Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity, Duke Partnership Wins $10.4M BARDA Extension for Biodosimeter Development

NEW YORK (GenomeWeb) – Duke University has been awarded $10.4 million from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to continue the development with DxTerity Diagnostics of a genetic test for radiation exposure.  

The funds extend the project's contract to early 2016 and bring total funding for the project to $43 million since 2009. An initial partnership between Duke, the University of Arizona, and DxTerity was established that year to develop a high-throughput, automated, direct-from-blood system for large-scale detection of RNA biomarkers indicating radiation exposure.

A molecular biodosimeter would be useful to triage patients after a nuclear disaster or mass radiation exposure since low-level exposure does not result in obvious initial symptoms, the partners said.

In a statement, DxTerity officials said the firm plans to seek US Food and Drug Administration approval of the biodosimeter within the next three years.

"If cleared, the radiation absorption test would be the first direct-from-blood, multiplex gene expression test approved by the FDA, and would open the door for other direct-from-blood gene assays," Bob Terbrueggen, DxTerity's founder and CEO said.

Rancho Dominguez, Calif.-based DxTerity received a Small Business Innovation Research contract in late 2013 to further translate its technology into a test for radiation sickness susceptibility to help manage patients undergoing cancer treatment. It continues to seek partners for its technology and recently launched a line of at-home blood collection tubes and reagent kits for multiplex PCR that use its RNA-stabilization chemistry.  

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.